Healthcare Industry News:  Cough 

Biopharmaceuticals

 News Release - January 29, 2008

Duska Therapeutics Completes Corporate Office Relocation to La Jolla

LA JOLLA, Calif., Jan. 29, 2008 (Healthcare Sales & Marketing Network) -- Duska Therapeutics, Inc., (OTC BB:DSKA.OB ), a biopharmaceutical company developing diagnostic and therapeutic products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that it has relocated its corporate offices from Bala Cynwd, Pennsylvania, to La Jolla, California. Duska's new address is 470 Nautilus Street, Suite 300, La Jolla, CA, 92037. The company's new telephone is (858) 551-5700.

According to BIOCOM, a life science industry organization representing hundreds of member companies in Southern California, there are approximately 36,600 employees in the life science community in San Diego County at more than 500 companies, including traditional biotech, medical device, diagnostic and technology companies.

``Access to experienced biotechnology expertise is a primary factor in our decision to relocate our corporate offices to La Jolla,'' said Dr. James S. Kuo, M.B.A., Chairman and CEO of Duska. ``We believe the La Jolla area offers the optimal combination of drug development experience and high quality of life for our associates that will build shareholder value in coming months.''

About Duska Therapeutics, Inc.

Duska Therapeutics focuses on the development of diagnostic and therapeutic products related to adenosine 5'-triphosphate (ATP), and cell-surface P2 receptors (P2R). Duska owns or has exclusive license rights to a number of proprietary diagnostic and therapeutic applications, four of which are currently in various stages of development in the fields of cardiac arrhythmias, male infertility, chronic obstructive pulmonary disorders and Cough, and glaucoma. For more information, visit Duska's website at http://www.duskatherapeutics.com.

Forward-looking statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as ``anticipates,'' ``expects,'' ``intends,'' ``plans,'' ``believes,'' ``seeks,'' ``estimates,'' or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska, including beliefs as to the benefits of being located in La Jolla and building shareholder value are forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Source: Duska Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.
RepFinder 2 - available on the Apple App Store for iPhone and iPad.